New cholesterol guidelines, new treatment challenges

Pharmacotherapy

Volumn 22, Issue 7, 2002, Pages 853-863

  McKenney, James M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID; CERIVASTATIN; CHOLESTEROL; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PITAVASTATIN; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEALTH EDUCATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; MUSCLE DISEASE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED STATES; BLOOD; CORONARY ARTERY DISEASE; DIET THERAPY; RISK FACTOR; STANDARD; STATISTICS;

CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; PRACTICE GUIDELINES; RISK FACTORS;

EID: 0035990376     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.11.853.33623     Document Type: Review

References (56)

1. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the multiple risk factor intervention trial (MRFIT)
2. Relationship of baseline cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity (lipid research clinics program)
3. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease
4. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study
5. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow-up report from the POSCH
6. Fifteen-year mortality in coronary drug project patients: Long-term benefit with niacin
7. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
8. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (the long-term intervention with pravastatin in ischaemic disease [LIPID] study group)
10. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
12. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
13. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, Air Force/Texas coronary atherosclerosis prevention study
14. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
15. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial
16. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
17. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials
18. Reduction of stroke incidence after myocardial infarction with pravastatin. The cholesterol and recurrent events (CARE) study
19. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II)
20. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III)
21. Hypertriglyceridemia as a cardiovascular risk factor
22. Triglycerides and atherogenic lipoproteins: Rationale for lipid management
23. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein goals
24. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
25. Statins: Effective antiatherosclerotic therapy
26. The evolving role of statins in the management of atherosclerosis
27. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
28. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolemia: The pivotal placebo-controlled clinical trial
29. Cerivastatin and reports of fatal rhabdomyolysis
30. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
31. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
32. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
33. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
34. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
35. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia
36. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia
37. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia
38. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
39. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/d1 in patients with hyperlipidemia and coronary artery disease
40. Niacin plus simvastatin, but not antioxidant vitamins, protect against atherosclerosis and clinical events in CAD patients with low HDL
41. Fibrates and statins in the treatment of hyperlipidemia: An appraisal of their efficacy and safety
42. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia
43. Omega-3 fatty acids: Time for clinical implementation?
44. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report from the Lyon diet heart study
45. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI prevenzione trial
46. Effect of pravastatin and ω-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia
47. Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
48. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
49. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
50. ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygous familial hypercholesterolemia
51. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
52. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
53. Selective cholesterol absorption inhibitors: A new class of drugs for lipid management
54. Roles of PPARs in health and disease